At Johnson & Johnson we believe that innovation is at the heart of human progress. As the world’s most broadly based health care company, we view innovation as a critical engine of our long-term business success. We rely on the transformative power of scientific knowledge, technology and collaboration to uncover innovative solutions to some of the biggest medical challenges of our time, including global pandemics, obesity, and the health issues linked to environmental degradation.
The way we are approaching innovation goes beyond products and services. We are innovating how we go to market, how we reach new consumers, and how we use technology to drive better outcomes and deliver long-term value to patients, consumers and customers around the world.
Johnson & Johnson began as an innovative startup in 1886 and has since built a strong track record in delivering innovative products that meet patients’ needs in every market where we operate.
From achieving scientific breakthroughs in tackling the world’s most pressing health challenges, to applying innovative thinking in product design to reduce environmental footprint, to exploiting latest technologies in the workplace that improve health and productivity of our employees, innovation is deeply ingrained in our culture at Johnson & Johnson.
Our unique approach to innovation combines several characteristics: a strong internal focus on research and development, strategic partnerships to harness the external opportunities for innovation, and emphasis on geography—specific health care solutions that account for differences in patient and customer needs across the world.
Guided by Our Credo, innovation at Johnson & Johnson starts with the patient needs. In each of our business segments, we prioritize the product pipeline based on the opportunity to address unmet medical needs and improve the lives of patients and consumers. We also consider the potential for commercial success. Recognizing that the best ideas can come from anywhere, we combine internal scientific strength with strategic external collaboration in the following R&D efforts:
In addition to this more traditional R&D focus, we are working to redefine what it means to innovate in low-resource settings by forming unconventional partnerships and accelerating the pace of socially beneficial innovation needed to deepen our impact. For example, in partnership with governments and civil society organizations, we are tackling some of the most serious public health challenges, such as multidrug-resistant tuberculosis and HIV/AIDS.
Beyond the lab, our approach to fostering innovation extends to our business strategy and employee development efforts. As the world of health care intersects more rapidly with the world of high technology, Johnson & Johnson is shaping this transformation in the industry by establishing "best-in-breed" technology partnerships and making equity investments in health tech. Our enterprise health tech strategy guides us towards building a flexible, secure digital business, developing smart products and creating new models of engagement.
In 2016, our R&D investments totaled $9.1 billion, which represents 12.7 percent of total revenue and demonstrates our commitment to Our Credo stakeholders that we manage the company for the long term.
As part of ongoing portfolio management, we announced the engagement in a process to evaluate potential strategic options for the Johnson & Johnson Diabetes Care Companies, specifically LifeScan, Inc., Animas Corporation, and Calibra Medical, Inc. Strategic options may include the formation of operating partnerships, joint ventures or strategic alliances, a sale of the businesses, or other alternatives either separately or together.
Johnson & Johnson announced collaboration with an HP Inc. subsidiary to create personalized health care solutions with 3D printing technologies, with the collaboration focused on improving outcomes, increasing satisfaction and reducing costs for patients, consumers and health care providers.
Examples of business segment innovation achievements follow:
With a repeatable insight-led innovation model for our Consumer business segment that led to more than 100 new products launched in 2016, we are proud of the support and endorsement by hospitals, health care professionals and consumers.
Also in 2016, our Johnson & Johnson Health and Wellness Solutions, Inc. announced a collaboration with Plug and Play Tech Center, a global investor and technology accelerator, to support innovative, early-stage companies developing direct-to-consumer solutions that enhance wellness.
Our surgical intervention solutions improve outcomes and reduce costs through sustainable behavioral change with our collaboration among Johnson & Johnson Health and Wellness Solutions, DePuy Synthes and IBM Watson Health, and through new models of engagement, such as the 2016-announced strategic collaboration between LifeScan, Inc. and WellDoc Corporation to advance mobile solutions that can empower Type 2 diabetes patients with real-time data and information to improve their health outcomes.
A dynamic example of our efforts to change the state of global surgery innovation is Verb Surgical Inc.—a recent collaboration between Ethicon and research company Verily Life Sciences LLC. By combining Ethicon’s expertise in minimally invasive tools and Verily’s vast knowledge of technology, Verb Surgical aims to create a comprehensive surgical solutions platform that can help advance the field of robotic-assisted surgery.
Johnson & Johnson was ranked #2 on the Access to Medicines Index (ATMI), up from #3 in 2014. ATMI is an independent evaluation that ranks the top 20 research-based pharmaceutical companies on providing access to medicines in developing countries. This achievement is a testament to our long-standing commitment to improving access to medicines in the developing countries.
Janssen won the International Prix Galien Award in recognition of our accomplishment in developing a ground-breaking therapy for multidrug-resistant tuberculosis .
Through the WIPO Research Initiative, Janssen provided access to its molecular library on a case-by-case basis to researchers globally to identify molecules that are potentially active against neglected tropical diseases and other diseases prevalent in the developing world. Janssen entered into multiple bilateral agreements in 2016 to address disease such as Chagas disease and Dengue Fever.
Janssen hosted the $85 million DREAMS Innovation Challenge—which aims to identify and support innovative ideas to reduce HIV infections in adolescent girls and young women in 10 sub-Saharan African countries—and directly funded three challenge winners, whose projects will reach 15,000 adolescent girls and young women in two countries in 2017 and 2018.
A public-private partnership of some of the world’s leading health organizations announced that data from a Phase 1 study of a preventive Ebola vaccine regimen have been published in JAMA: The Journal of the American Medical Association. The results suggest that the regimen was well tolerated by healthy volunteers and immunogenic (produced an immune response). Among the findings, 100 percent of participants in the study achieved an initial antibody response to Ebola, which was sustained eight months following immunization.
The findings from a two-year study published in Nature in 2016, in which Janssen participated as co-author, suggest that combining therapeutic vaccination with immune stimulation could be a potential way to achieve a functional cure for HIV infection, a strategy to suppress HIV infection long-term without the need for life-long antiretroviral therapy .
To support African innovation community to accelerate clinical innovation by Africans for Africa, we announced a partnership with the University of Cape Town’s Drug Discovery and Development Center.